Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 112 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR Low-Dose Pembrolizumab with Dose-Dense Chemotherapy Increases pCR as Neoadjuvant Treatment for Localised TNBC ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma MOST POPULAR Exposure to Antibiotics, Specifically Fluoroquinolones, Before Treatment with Immune Checkpoint Inhibitor... March 6, 2023 Studies Provide First Evidence That Breastfeeding after Breast Cancer Is Safe September 8, 2024 Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients... May 7, 2026 EMA Recommends Granting a Marketing Authorisation for Piflufolastat (18F) June 1, 2023 Load more HOT NEWS Inaugural ESMO Targeted Anticancer Therapies Asia Congress 2025, Hong Kong SAR,... “Nothing about us without us”: Why we’re working in partnership with... Repotrectinib Expands Treatment Options for Lung Cancers with ROS1 Fusions 2023 ASCO Annual Meeting Research Round Up: Progress in Treating Breast...
